Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials
-
Published:2021-01
Issue:1
Volume:79
Page:44-53
-
ISSN:0302-2838
-
Container-title:European Urology
-
language:en
-
Short-container-title:European Urology
Author:
Abufaraj Mohammad,
Iwata Takehiro,
Kimura Shoji,
Haddad AnoudORCID,
Al-Ani Hashim,
Abusubaih LanaORCID,
Moschini Marco,
Briganti Alberto,
Karakiewicz Pierre I.,
Shariat Shahrokh F.
Reference28 articles.
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018
2. Degarelix: a new approach for the treatment of prostate cancer;Persson;Neuroendocrinology,2009
3. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists;Van Poppel;Int J Urol,2012
4. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer;Klotz;BJU Int,2008
5. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study;Schröder;BJU Int,2010
Cited by
73 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献